Stroke – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Stroke – Pipeline Review, H1 2017’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Stroke

The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects

The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Stroke

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Stroke

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Acticor Biotech SAS

ActiveSite Pharmaceuticals Inc

Addex Therapeutics Ltd

Affibody AB

Anavex Life Sciences Corp

Angion Biomedica Corp

Antoxis Ltd

ArmaGen Inc

Artielle ImmunoTherapeutics Inc

Asterias Biotherapeutics Inc

Athersys Inc

Bayer AG

Bioasis Technologies Inc

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cardax Inc

Cellular Biomedicine Group Inc

CHA Bio & Diostech Co Ltd

ContraVir Pharmaceuticals Inc

CSPC Pharmaceutical Group Limited

D-Pharm Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Diffusion Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fina Biotech SL

Genervon Biopharmaceuticals LLC

Glialogix Inc

Glucox Biotech AB

Green Cross Corp

Huons Co Ltd

Immunwork Inc

International Stem Cell Corp

Jeil Pharmaceutical Co Ltd

JN-International Medical Corp

JT Pharmaceuticals Inc

Les Laboratoires Servier SAS

Living Cell Technologies Ltd

Lumosa Therapeutics Co Ltd

M et P Pharma AG

Magnus Life Ltd

Mapreg SAS

Medestea Research & Production SpA

Mitochon Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

Neuronax SAS

NeuroSearch A/S

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NoNO Inc

Novartis AG

NuvOx Pharma LLC

Omeros Corp

Omniox Inc

Panacea Pharmaceuticals Inc

Pharmaxis Ltd

Pharmicell Co Ltd

Phoenix Biotechnology Inc

PhytoHealth Corp

Pluristem Therapeutics Inc

QR Pharma Inc

ReCyte Therapeutics Inc

Remedy Pharmaceuticals Inc

ReNeuron Group Plc

Rubicon Biotechnology Inc

SanBio Inc

Saneron CCEL Therapeutics Inc

Savara Inc

Shin Poong PharmCo Ltd

Simcere Pharmaceutical Group

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Tasly Pharmaceutical Group Co Ltd

TikoMed AB

Verseon Corp

Vicore Pharma AB

Virogenomics BioDevelopment Inc

WhanIn Pharmaceutical Co Ltd

Zocere Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Stroke - Overview 7

Stroke - Therapeutics Development 8

Stroke - Therapeutics Assessment 30

Stroke - Companies Involved in Therapeutics Development 46

Stroke - Drug Profiles 88

Stroke - Dormant Projects 418

Stroke - Discontinued Products 427

Stroke - Product Development Milestones 430

Appendix 442

List of Tables

List of Tables

Number of Products under Development for Stroke, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Stroke – Pipeline by AB Science SA, H1 2017

Stroke – Pipeline by Acticor Biotech SAS, H1 2017

Stroke – Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by Addex Therapeutics Ltd, H1 2017

Stroke – Pipeline by Affibody AB, H1 2017

Stroke – Pipeline by Anavex Life Sciences Corp, H1 2017

Stroke – Pipeline by Angion Biomedica Corp, H1 2017

Stroke – Pipeline by Antoxis Ltd, H1 2017

Stroke – Pipeline by ArmaGen Inc, H1 2017

Stroke – Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017

Stroke – Pipeline by Asterias Biotherapeutics Inc, H1 2017

Stroke – Pipeline by Athersys Inc, H1 2017

Stroke – Pipeline by Bayer AG, H1 2017

Stroke – Pipeline by Bioasis Technologies Inc, H1 2017

Stroke – Pipeline by Biogen Inc, H1 2017

Stroke – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Stroke – Pipeline by Bristol-Myers Squibb Company, H1 2017

Stroke – Pipeline by Cardax Inc, H1 2017

Stroke – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Stroke – Pipeline by CHA Bio & Diostech Co Ltd, H1 2017

Stroke – Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by CSPC Pharmaceutical Group Limited, H1 2017

Stroke – Pipeline by D-Pharm Ltd, H1 2017

Stroke – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Stroke – Pipeline by DiaMedica Therapeutics Inc, H1 2017

Stroke – Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Stroke – Pipeline by Fina Biotech SL, H1 2017

Stroke – Pipeline by Genervon Biopharmaceuticals LLC, H1 2017

Stroke – Pipeline by Glialogix Inc, H1 2017

Stroke – Pipeline by Glucox Biotech AB, H1 2017

Stroke – Pipeline by Green Cross Corp, H1 2017

Stroke – Pipeline by Huons Co Ltd, H1 2017

Stroke – Pipeline by Immunwork Inc, H1 2017

Stroke – Pipeline by International Stem Cell Corp, H1 2017

Stroke – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Stroke – Pipeline by JN-International Medical Corp, H1 2017

Stroke – Pipeline by JT Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by Les Laboratoires Servier SAS, H1 2017

Stroke – Pipeline by Living Cell Technologies Ltd, H1 2017

Stroke – Pipeline by Lumosa Therapeutics Co Ltd, H1 2017

Stroke – Pipeline by M et P Pharma AG, H1 2017

Stroke – Pipeline by Magnus Life Ltd, H1 2017

Stroke – Pipeline by Mapreg SAS, H1 2017

Stroke – Pipeline by Medestea Research & Production SpA, H1 2017

Stroke – Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Stroke – Pipeline by Neuralstem Inc, H1 2017

Stroke – Pipeline by Neuren Pharmaceuticals Ltd, H1 2017

Stroke – Pipeline by Neurofx Inc, H1 2017

Stroke – Pipeline by Neuronax SAS, H1 2017

Stroke – Pipeline by NeuroSearch A/S, H1 2017

Stroke – Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Stroke – Pipeline by New World Laboratories Inc, H1 2017

Stroke – Pipeline by NoNO Inc, H1 2017

Stroke – Pipeline by Novartis AG, H1 2017

Stroke – Pipeline by NuvOx Pharma LLC, H1 2017

Stroke – Pipeline by Omeros Corp, H1 2017

Stroke – Pipeline by Omniox Inc, H1 2017

Stroke – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by Pharmaxis Ltd, H1 2017

Stroke – Pipeline by Pharmicell Co Ltd, H1 2017

Stroke – Pipeline by Phoenix Biotechnology Inc, H1 2017

Stroke – Pipeline by PhytoHealth Corp, H1 2017

Stroke – Pipeline by Pluristem Therapeutics Inc, H1 2017

Stroke – Pipeline by QR Pharma Inc, H1 2017

Stroke – Pipeline by ReCyte Therapeutics Inc, H1 2017

Stroke – Pipeline by Remedy Pharmaceuticals Inc, H1 2017

Stroke – Pipeline by ReNeuron Group Plc, H1 2017

Stroke – Pipeline by Rubicon Biotechnology Inc, H1 2017

Stroke – Pipeline by SanBio Inc, H1 2017

Stroke – Pipeline by Saneron CCEL Therapeutics Inc, H1 2017

Stroke – Pipeline by Savara Inc, H1 2017

Stroke – Pipeline by Shin Poong PharmCo Ltd, H1 2017

Stroke – Pipeline by Simcere Pharmaceutical Group, H1 2017

Stroke – Pipeline by Stemedica Cell Technologies Inc, H1 2017

Stroke – Pipeline by SynZyme Technologies LLC, H1 2017

Stroke – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Stroke – Pipeline by TikoMed AB, H1 2017

Stroke – Pipeline by Verseon Corp, H1 2017

Stroke – Pipeline by Vicore Pharma AB, H1 2017

Stroke – Pipeline by Virogenomics BioDevelopment Inc, H1 2017

Stroke – Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017

Stroke – Pipeline by Zocere Inc, H1 2017

Stroke – Dormant Projects, H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..1), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..2), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..3), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..4), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..5), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..6), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..7), H1 2017

Stroke – Dormant Projects, H1 2017 (Contd..8), H1 2017

Stroke – Discontinued Products, H1 2017

Stroke – Discontinued Products, H1 2017 (Contd..1), H1 2017

Stroke – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Stroke, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports